Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=38734884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057161(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/262,113external-prioritypatent/US20060189635A1/en
Application filed by Alza CorpfiledCriticalAlza Corp
Publication of AR057161A1publicationCriticalpatent/AR057161A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Abstract
Se revelan método y forma de dosificacion que comprenden derivados de benzisoxazol. Más particularmente, se revelan métodos, formas de dosificacion, y nuevos usos de derivados de benzisoxazol que proveen eficacia cuando se utilizan en el tratamiento de la esquizofrenia y/o de la manía bipolar. Reivindicacion 1: El uso de un derivado de benzisoxazol para preparar un medicamento como una forma de dosificacion de liberacion sostenida oral para administrar en forma sostenida y por vía oral una cantidad con eficacia mejorada el derivado de benzisoxazol para el tratamiento de la esquizofrenia, donde la cantidad con eficacia mejorada del derivado de benzisoxazol oscila entre 2 mg y 18 mg.Method and dosage form comprising benzisoxazole derivatives are disclosed. More particularly, methods, dosage forms, and new uses of benzisoxazole derivatives are disclosed that provide efficacy when used in the treatment of schizophrenia and / or bipolar mania. Claim 1: The use of a benzisoxazole derivative to prepare a medicament as an oral sustained release dosage form to sustainably and orally administer an amount with improved efficacy the benzisoxazole derivative for the treatment of schizophrenia, wherein the Effectively improved amount of benzisoxazole derivative ranges from 2 mg to 18 mg.
ARP0601045682005-10-192006-10-19
METHODS AND DOSAGE FORMS OF BENZISOXAZOL DERIVATIVES WITH BETTER EFFECTIVENESS
AR057161A1
(en)
A phosphodiesterase 7 (pde7) inhibitory agent to be used in the treatment or reduction of the possibility of an addiction; and pharmaceutical composition, unit dosage form and pharmaceutical kit including phosphodiesterase 7 inhibitor (pde7) and an additional therapeutic agent.
Solid and stabilized pharmaceutical composition comprising a pharmaceutically active ingredient, titanium oxide and a plasticizer; procedure to stabilize the pharmaceutical composition during a light irradiation.
Compounds derived from quinoline-carboxamide, antagonists of p2y12; preparation procedure; pharmaceutical composition comprising said compound; composition of a combination of said compounds; and use of the compound in the treatment of cardiovascular disorders, thromboembolism, acute myocardial infarction.
COMPOSITION IN THE FORM OF TRANSDERMIC OR TRANSMUCOSE DOSAGE THAT INCLUDES A RELATIONSHIP IN BUPRENORFINE WEIGHT TO NALOXONE BETWEEN 2.1: 1 AND 8: 1, USEFUL FOR THE TREATMENT OF PAIN.
compound, pharmaceutical composition, methods for inhibiting the action of glycogen synthase kinase-3, and for treating, preventing or ameliorating a disease, use of a compound, and article of manufacture
Pharmaceutical composition for oral administration comprising bendamustine or an ester, a salt or a solvate thereof, and an excipient which is a non-ionic and hydrophilic surfactant; pharmaceutical combination; and its use for the treatment of chronic lymphocytic leukemia and multiple myeloma, among other diseases.
ANALGESIC COMPOSITION IN THE FORM OF UNIT PARENTERAL DOSAGE OR IN A SUITABLE UNIT DOSAGE FORM FOR AN ADMINISTRATION BY THE MUCOSA OR THE DERMIS THAT INCLUDES BUPRENORFINE AND NALMEN, USEFUL FOR THE TREATMENT OF PAIN.
Pharmaceutical composition composed of the synergistic combination of an anticonvulsant agent such as gabapentin and a non-steroidal anti-inflammatory agent such as meloxicam, the concentration ranges present for gabapentin are 3 to 300 mg and 0.1 to 30 mg for meloxicam; and use to treat neuropathic pain
Solid oral dosage form comprising alisquirene alone or in combination with another active agent; Preparation process; and use in the treatment of diseases such as hypertension, angina, atherosclerosis, among others.